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Objective:There iswidespread evidence that cancer confers an increased risk of deep venous thrombosis (DVT).This risk is thought
to vary amongdifferent cancer types. The purpose of this study is to better define the incidence of thrombotic complications among
patients undergoing surgical treatment for a spectrum of prevalent cancer diagnoses in contemporary practice.
Methods: All patients undergoing one of 11 cancer surgical operations (breast resection, hysterectomy, prostatectomy,
colectomy, gastrectomy, lung resection, hepatectomy, pancreatectomy, cystectomy, esophagectomy, and nephrectomy) were
identified by Current Procedural Terminology and International Classification of Diseases, Ninth Revision codes using the
American College of Surgeons National Surgical Quality Improvement Program database (2007-2009). The study endpoints
wereDVT, pulmonary embolism (PE), and overall postoperative venous thromboembolic events (VTE)within 1month of the
index procedure. Multivariate logistic regression was utilized to calculate adjusted odds ratios for each endpoint.
Results:Over the study interval, 43,808 of the selected cancer operations were performed. The incidence of DVT, PE, and
total VTE within 1 month following surgery varied widely across a spectrum of cancer diagnoses, ranging from 0.19%,
0.12%, and 0.28% for breast resection to 6.1%, 2.4%, and 7.3%, respectively, for esophagectomy. Compared with breast
cancer, the incidence of VTE ranged from a 1.31-fold increase in VTE associated with gastrectomy (95% confidence
interval, 0.73-2.37; P  .4) to a 2.68-fold increase associated with hysterectomy (95% confidence interval, 1.43-5.01;
P  .002). Multivariate logistic regression revealed that inpatient status, steroid use, advanced age (>60 years), morbid
obesity (body mass index >35), blood transfusion, reintubation, cardiac arrest, postoperative infectious complications,
and prolonged hospitalization were independently associated with increased risk of VTE.
Conclusions:The incidence of VTE and thromboembolic complications associated with cancer surgery varies substantially.
These findings suggest that both tumor type and resection magnitude may impact VTE risk. Accordingly, such data
support diagnosis and procedural-specific guidelines for perioperative VTE prophylaxis and can be used to anticipate the
risk of potentially preventable morbidity. ( J Vasc Surg 2012;55:1035-41.)
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nDeep venous thrombosis (DVT) and pulmonary embo-
lism (PE) constitute the spectrum of venous thromboembo-
lism (VTE) and remain prevalent causes of mortality and
morbidity.1 Accordingly, several nationalmedical and surgical
organizations, including the American College of Surgeons,
have made detection and prevention of VTE a focus for
patient safety initiatives.2-4 DVT and PE are currently re-
corded in the American College of Surgeons (ACS) National
Surgical Quality Improvement Program (NSQIP) as postop-
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doi:10.1016/j.jvs.2011.10.129rative complications, and are considered by many to be an
mportant quality indicator in surgery.2
Currently, there is widespread consensus that certain
atient populations are believed to be at higher risk for
TE. Specifically, malignancy has been associated with a
ix- to sevenfold increased risk of venous thrombosis5,6 and
ay result in a threefold increase in PE.7 Interestingly, this
isk may vary substantially based on the specific associated
alignancy type.5,8,9 Deep venous thrombosis rates have
een shown to vary from 2% to 34% among patients with
arious different localized cancers, while metastatic disease
ppears to confer an increased supplemental risk.8 Among
atients undergoing surgical resection for specific malig-
ancies, VTE remains a major cause for mortality10 and
ay serve as an important predictor of overall survival.9
ccordingly, patients undergoing surgical resection for
ancer are at high risk for VTE and require prophylaxis.1
Currently, recommendations for VTE prophylaxis are
oncordant for most cancer types, despite the variation in
ssociated VTE risk among specific malignancies. The pur-
ose of this study was to better define the incidence and
mpact of surgical therapy on rates of DVT, PE, and overall
TE among patients with clinically prevalent cancer diag-
oses. In addition, we sought to identify specific peripro-
edural risk factors associated with VTE in this high-risk
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April 20121036 De Martino et alpatient population, to better identify processes of care to
reduce the incidence of VTE and potentially improve out-
comes in patients undergoing cancer surgery.
METHODS
NSQIP dataset and study population. The Ameri-
can College of Surgeons National Surgical Quality Improve-
ment Program (ACS-NSQIP) is a multi-institutional cohort
study of patients undergoing surgery within participating hos-
pitals. Data are recorded on preoperative, operative, and post-
operative outcomes for 30 days after the index procedure.
Participant hospitals are provided risk-adjusted outcomes for
quality improvement purposes. Data abstraction and variable
definitions are available from the ACS-NSQIP Web site.11
Patients who underwent breast surgery, gastrectomy, lung
resection, prostatectomy, colectomy, pancreatectomy, esoph-
agectomy, hysterectomy, hepatectomy, cystectomy, and ne-
phrectomy were identified using the ACS-NSQIP Participant
Use File for 2007-2009. Cases were identified by primary
procedural Current Procedural Terminology (CPT-9 CM)
codes and International Classification of Diseases, Ninth Re-
vision (ICD-9) codes for malignant disease to identify cases
performed for cancer (Appendix A, online only). Cases done
for benign diagnoses were excluded from analysis.
Definition of DVT, PE and VTE. Our endpoints for
analysis were postoperative DVT, PE, and overall VTE.
DVT/phlebitis is currently defined within ACS-NSQIP as
the “identification of a new blood clot or thrombus within
the venous system, which may be coupled with inflamma-
tion within 30 days of the operation. This diagnosis is
confirmed by a duplex [ultrasound], venogram or [com-
puted tomography] CT scan. The patient must be treated
with anticoagulation therapy or placement of a vena cava
filter or clipping of the vena cava.” PE is defined as “lodging
of a blood clot in a pulmonary artery with subsequent
Fig 1. Incidence of deep venous thrombosis (DVT) po
within National Surgical Quality Improvement Programobstruction of blood supply to the lung parenchyma. PE tis] documented if the patient has a [ventilation/perfusion]
-Q scan interpreted as high probability of pulmonary
mbolism or a positive CT spiral exam, pulmonary arterio-
ram, or CT angiogram.”11 VTE is defined as the presence
f DVT and/or PE during the postoperative period.
Statistical analysis. Preoperative, operative, and post-
perative variables were compared for each endpoint using 2
or categorical variables. A two-sample t-test or Wilcoxon
ank-sum test was used to compare parametric or nonpara-
etric continuous variables, respectively. Variables of clinical
ignificance and those with a P value of .05 by univariate
nalysis were included in a backward stepwisemultiple logistic
egression to identify significant predictors for each outcome.
ariables were removed using the likelihood-ratio test. Con-
inuous variables with nonlinear risk were categorized for
ogistic analysis. Probability values of .05 were considered
ignificant. All analyses were performed with Stata Release 11
STATA Corp, College Station, Tex).
ESULTS
Incidence of thromboembolic complications.
ithin the ACS-NSQIP (2007-2009), we identified
3,808 cancer patients undergoing one of 11 surgeries:
reast resection (17.7%), gastrectomy (5.4%), lung resec-
ion (3.2%), prostatectomy (6.8%), colectomy (36.7%),
ancreatectomy (12.6%), esophagectomy (2.5%), hysterec-
omy (3.7%), hepatectomy (8.5%), cystectomy (0.7%), and
ephrectomy (2.2%). The incidence of postoperative DVT,
E, and VTE varied substantially among specific proce-
ures. Associated DVT rates ranged from 0.19% for breast
urgery to 6.1% for esophagectomy (Fig 1). The rates of PE
anged from 0.12% for breast surgery to 3.1% for cystec-
omy (Fig 2). Overall VTE rates ranged from 0.28% for
reast surgery to 7.28% for esophagectomy (Fig 3).
Predictors of DVT. Compared with breast resec-
ratively or within 30 days from index cancer operation
IP) (2007-2009).stopeion, major intra-abdominal operations, such as prosta-
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Volume 55, Number 4 De Martino et al 1037tectomy (odds ratio [OR], 2.49, 95% confidence interval
[CI], 1.24-4.99), colectomy (OR, 2.12; 95% CI, 1.2-
3.75), esophagectomy (OR, 3.64; 95% CI, 1.9-6.95),
hysterectomy (OR, 2.95; 95% CI, 1.44-6.03), and hep-
atectomy (OR, 2.18; 95% CI, 1.16-4.05), had twofold
or greater odds of postoperative DVT (Table I). By
multivariate analysis, recent steroid use, age (60 years),
a body mass index (BMI) 35 kg/m2, longer operative
time, and blood transfusions were associated with in-
creased odds of DVT (Table II). Additionally, postoper-
ative complications, such as wound infection, reintuba-
tion, PE, peripheral nerve injury, and postoperative
sepsis also increased the odds of DVT. Extended length
Fig 2. Incidence of pulmonary embolism (PE) postope
National Surgical Quality Improvement Program (NSQ
Fig 3. Incidence of venous thromboembolism (VTE) pos
National Surgical Quality Improvement Program (NSQIP) (2of stay was associated with a 2.9- to 7.2-times increased ndds in DVT compared to shorter lengths of stay (1
eek) (Table II; Appendix B, online only).
Predictors of PE. Like DVT, the odds of PE varied by
peration as well. Compared with breast resection, every
peration except for esophagectomy had over a twofold
ncreased odds of PE (Table I). Additionally, hysterectomy
OR, 5.51; 95% CI, 2.41-12.6) and cystectomy (OR, 6.39;
5% CI, 2.4-17.01) conferred a much higher risk of post-
perative PE. By multivariate analysis, recent radiation
reatment, thrombocytosis (platelets400.000), and post-
perative complications such as wound infection, reintuba-
ion, DVT, urinary tract infection, and cardiac arrest all
ere associated with increased odds of PE (Table II). Of
ly or within 30 days from index cancer operation within
007-2009).
atively or within 30 days from index cancer operationwithin
2009).rativetoperote, prolonged hospital length of stay conferred a 3.03 to
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April 20121038 De Martino et al6.44 odds of PE compared with shorter in-hospital length
of stay (1 week). Interestingly, low BMI (25 kg/m2)
and postoperative dialysis reduced the odds of PE (Table
III, Appendix C, online only).
Predictors of VTE. Among the 135 patient-level
variables recorded in the ACS-NSQIP, 60 perioperative
variables were associated with the development of VTE,
our composite endpoint, by univariate comparison (Appen-
dix D, online only). Compared with breast resection, pros-
tatectomy (OR, 2.17; 95% CI, 1.17-4.02), esophagectomy
(OR, 2.26; 95% CI, 1.24-4.12), hysterectomy (OR, 2.68;
95% CI, 1.43-5.01), and hepatectomy (OR, 1.92; 95% CI,
Table I. Adjusted odds ratios of DVT, PE, and overall VT
College of Surgeons National Surgical Quality Improveme
Case
DVT
OR 95% CI P O
Breast resection 1.0 (ref) 1.0 (
Gastrectomy 1.6 0.8-3.0 .17 3.
Lung resection 1.8 0.8-3.7 .12 3.
Prostatectomy 2.5 1.2-5.0 .01 3.
Colectomy 2.1 1.2-3.8 <.01 2.
Pancreatectomy 1.6 0.1-2.9 .15 2.
Esophagectomy 3.6 1.9-7.0 <.01 2.
Hysterectomy 2.9 1.4-6.0 <.01 5.
Hepatectomy 2.2 1.2-4.1 .01 3.
Cystectomy 1.6 0.6-4.1 .29 6.
Nephrectomy 1.3 0.5-3.5 .63 4.
CI, Confidence interval; DVT, deep vein thrombosis; OR, odds ratio; PE, p
Bolded variables indicate P  .05.
Table II. Multivariate predictors of increased odds of DV
Variables OR for DVTa (95% CI, P)
Recent steroid use 1.5 (1.0-2.3, .04)
Recent radiation therapy —
Age 60 years 1.6 (1.2-2.2, .01)
1.8 (1.2-2.5, .01)
Body mass index 35 1.5 (1.2-2.0, .01)
Platelets 400 K —
Transfusion 3 units 1.5 (1.1-2.1, .02)
3.4 (1.9-6.3, .01)
Deep infection 1.5 (1.2-1.9, .01)
Reintubated 1.5 (1.2-2.0, .01)
PE 11.5 (8.9-15.0, .01)
DVT —
Urinary tract infection —
Peripheral nerve injury 6.9 (2.5-19.2, .01)
Sepsis postoperation 1.5 (1.2-2.0, .01)
Shock postoperation 1.5 (1.1-2.1, .01)
Cardiac arrest —
Operative time
(minutes)
1.0 (1.0-1.001, .01)
Length of stay 1 week 2.9 (2.2-3.7, .01)
7.2 (4.4-11.7, .01)
CI, Confidence interval; DVT, deep venous thrombosis; OR, odds ratio; PE
aSee Appendix B (online only) for complete DVT multivariate model.
bSee Appendix C (online only) for complete PE multivariate model.
cSee Appendix E (online only) for complete VTE multivariate model.1.09-3.39) were found to confer a higher risk of VTE. pultivariate predictors of VTE included age (60-79 years),
ecent steroid use, BMI 35 kg/m2, and postoperative
omplications, including wound infection, reintubation,
ardiac arrest, and sepsis (Table II). Longer hospitalizations
onferred a 3.4 to 11.16 increased odds of VTE compared
ith shorter hospitalizations (1 week; Table II). Con-
ersely, admission prior to surgery, outpatient procedures,
nd low a BMI (25 kg/m2) conferred some benefit from
TE (Table III; Appendix E, online only).
ISCUSSION
Vascular surgeons are frequently consulted to optimize hos-
llowing selected cancer operations within the American
ogram (ACS-NSQIP) (2007-2009)
PE VTE
95% CI P OR 95% CI P
1.0 (ref)
1.4-6.6 <.01 1.3 0.7-2.4 .37
1.7-9.1 <.01 1.8 0.9-3.3 .08
1.6-8.9 <.01 2.2 1.2-4.0 .01
1.4-5.7 <.01 1.7 1.0-2.9 .05
1.4-6.0 <.01 1.3 0.8-2.3 .32
0.9-5.2 .08 2.3 1.2-4.1 <.01
2.4-12.6 <.01 2.7 1.4-5.0 <.01
1.8-8.3 .01 1.9 1.1-3.4 .0
2.4-17.0 <.01 1.8 0.9-3.9 .1
1.5-10.8 <.01 1.7 0.8-3.5 .2
ary embolism; VTE, venous thromboembolism.
, and VTE
OR for PEb (95% CI, P) OR for VTEc (95% CI, P)
— 1.4 (1.01-2.0, .04)
1.9 (1.2-3.2, .01) —
— 1.4 (1.1-1.9, .01)
— 1.3 (1.1-1.7, .01)
1.5 (1.1-2.0, .01) —
— 1.3 (1.0-1.8, .05)
2.3 (1.3-4.1, .01)
1.4 (1.0-2.0, .03) 1.5 (1.2-1.9, .01)
2.0 (1.4-2.8, .01) 1.7 (1.4-2.2, .01)
— —
11.2 (8.6-14.6, .01) —
1.8 (1.3-2.5, .01) —
— —
— 1.4 (1.1-1.7, .01)
— 1.3 (1.0-1.7, .04)
3.1 (1.9-5.2, .01) 1.9 (1.3-2.8, .02)
— —
3.0 (2.3-4.0, .01) 3.4 (2.8-4.1, .01)
6.4 (2.3-14.7, .01) 11.7 (7.8-17.5, .01)
onary embolism; VTE, venous thromboembolic event.E fo
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R
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undergone operative resection. Although there is a widespread
recognition forassociatedhypercoaguabilityamongpatientswith
malignancy, less is knownabout thepotential variation in throm-
botic complications in this presumptive high-risk group. More-
over, despite potential variations in the risk of VTE among
patients with different cancer diagnoses, there are few variations
in prophylactic care to prevent thesemorbid complications. This
study demonstrates that the risks ofDVT, PE, and concordantly
VTE, vary across the spectrum of neoplastic diagnoses. Specifi-
cally, these data suggest that patients undergoing prostatectomy,
esophagectomy, hysterectomy, and hepatectomy for cancer are
at increased risk of VTE. Interestingly, hospital length of stay
appears tobeoneof thegreatest risk factors associatedwithVTE.
Intuitively, patients undergoing cancer surgery remain
at a high risk for VTE as they meet criteria for Virchow’s
triad of hypercoaguability, stasis, and endothelial injury.
Furthermore, cancer has been shown in prior population-
based studies to carry a fourfold increased risk of VTE.6,12
The pathophysiology of hypercoagulability in cancer re-
mains complex and likely involves a series of cytokine
signaling, abnormal fibrinolysis, and dysfunctional platelet
adhesion.13 In addition, surgical resection may carry as
much as a 22-fold increased risk of VTE,6 whichmay still be
augmented by varying cancer type, adjuvant chemotherapy,
and the requisite need for indwelling catheters.13
Several studies have documented that the risk of VTE varies
by the typeof cancer.5,8,14Across studies, pancreatic, brain, lung,
stomach, andhematologicmalignancies remain associatedwith a
higher risk of VTE. In contrast, head and neck cancers, as well as
breastmalignancies, although still greater than control, appear to
have a lower associated thrombotic risk. Interestingly, although
perhaps not surprisingly, the presence of metastatic disease may
double the risk ofVTE.8This study demonstrates that the risk of
VTE also appears to vary by cancer procedure, in addition to
cancer type. Yet our analysis demonstrates that previously per-
ceived lower-risk malignancies such as prostate cancer, esopha-
geal cancer, and liver cancer may actually carry a higher risk of
VTEthanpreviouslybelieved.This findingmaybedue to several
differences in our study compared with others. Previous studies
have been predominantly epidemiologic in nature5,8 and not
specific to patients in the perioperative period. ACS-NSQIP
represents a special populationof cancer patients, and their risk of
VTE likely reflects a combination of both their specific cancer
Table III. Multivariate predictors of decreased odds of DV
Variables OR for DVTa (95% CI, P
Body mass index 25 —
Postoperative dialysis —
Outpatient status —
Days from admission to surgery —
CI, Confidence interval; DVT, deep venous thrombosis; OR, odds ratio; PE
aSee Appendix B (online only) for complete DVT multivariate model.
bSee Appendix C (online only) for complete PE multivariate model.
cSee Appendix E (online only) for complete VTE multivariate model.type as well as the magnitude of their surgery. Thus, it is not hnexpected forexample, thatesophageal cancermaycarryamore
ignificant increased risk of VTE, as this diagnosis often requires
n anatomic resection in both the abdomen and thorax. There-
ore, we believe these findings represent a novel analysis of VTE
isk among cancer patients.
The current American College of Chest Physicians
uidelines recommend pharmacologic VTE prophylaxis for
atients with multiple risk factors for thrombotic compli-
ations and for those undergoing moderate to major risk
urgical procedures. Patients at low risk and undergoing
ow-risk procedures do not require routine chemical pro-
hylaxis. Ongoing pharmacologic prophylaxis, however,
emains recommended for hospitalized cancer patients fol-
owing surgery, or those who are felt to be medically high
isk or bedridden.1 Interestingly, there is currently no
ariation in method or duration of prophylaxis among
ancer types, oncological procedures, or length of stay
espite a clear disparity in the risk of sustaining a throm-
otic event. Although length of stay alone as a risk factor for
he development of a DVT is not well established, the
ssociation of prolonged hospitalization, increased cost,
nd mortality referable to VTE is well known. Specifically,
TE may result in an additional 5 days of hospitalization,
n increased cost of $20,000, and a 6% increased mortality
n average based on National Inpatient Sample data.15
ased on these findings, this study may assist efforts to
educe VTE events in postoperative cancer patients, by
inimizing length of stay, including proper risk stratifica-
ion, vigilant prophylaxis, minimizing postoperative infec-
ious complications, and minimizing requisite transfusions.
AlthoughMerkow et al previously demonstrated a variation
n the incidence ofVTE in a similar patient population, the study
ocused more on associated rates of postdischarge VTE in an
ffort to recognize the potential need for prolonged prophy-
axis.16This study, incontrast,highlights theperioperative factors
hat may predispose patients to VTE. Thus, the model incorpo-
ated herein utilized additional variables, such as length of stay,
hich has been shown to increase the risk of DVT.17-19 Length
f stay is also a reflection of surgical magnitude and an effect of
verall complication rates. As these data point out, prolonged
ospital stay is a major risk factor for VTE, which may reflect
xtended bed rest and associated venous stasis. Thus, our esti-
ates of risk across cancer surgeries are more conservative as we
E, and VTE
OR for PEb (95% CI, P) OR for VTEc (95% CI, P)
0.7 (0.5-0.9, .01) 0.8 (0.7-0.9, .04)
0.4 (0.2-0.8, .02) —
— 0.5 (0.2-0.9, .02)
— 0.9 (0.9-0.97, .01)
onary embolism; VTE, venous thromboembolic event.T, P
)
, pulmave incorporated these important perioperative variables.
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retrospective data, we remain unable to prove causation be-
tween specific malignancy resection and thrombotic compli-
cations but rather only association. In addition, specific pa-
tient-level data remains unavailable within the ACS-NSQIP
public use file. Accordingly, we remain unable to identify
patients with prior VTE, who may be at higher risk for a
second event. Furthermore, specific VTE prophylaxis, such as
specific pharmacologic protocols, inferior vena cava filter use,
or sequential compression device use, may vary by both sur-
geon and facility, which could impact the observed rates of
variation. Lastly, anatomic features of DVTs (upper vs lower
extremity) or the presence of indwelling catheters remain
unknown, which may confound these results. Nevertheless,
these results do depict variation in thrombotic events associ-
ated with various malignancies in real-world contemporary
practice. Moreover, this analysis has identified both higher-
risk surgeries and independent predictors of DVT, PE, and
VTE, which may be considered in an attempt to diminish the
incidence of thesemorbid complications.These resultsmaybe
used to develop prospective cohort studies designed to vali-
date risk of VTE in patients undergoing various cancer surger-
ies. This will then be able to overcome the limitations of
observational data.
CONCLUSIONS
Patients with cancer remain at increased risk for VTE;
however, this appears to vary bymalignancy type. In addition,
variation in VTE risk among patients undergoing surgical
resection may differ not only by cancer but also by the associ-
ated resection magnitude. Among procedure types evaluated
herein, breast resection appears to have the lowest risk ofVTE,
while specific intra-abdominal and pelvic cancer resections
have the highest risk. These data further identify patients at
increased risk of VTE, such as thosewith increased age, length
of stay, BMI, and transfusion rates, as well as those with
infectious complications following cancer surgery. Clinicians
may use these findings to stratify patient risk for VTE follow-
ing operative resection in an attempt tominimize themorbid-
ity associated with DVT, PE, and VTE. Additionally, this
study may provide the basis for improved diagnosis and pro-
cedural-specific guidelines for perioperativeDVT and PE pro-
phylaxis.
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Procedure CPT code
Prostatectomy 55,801, 55,810, 55,831, 55,840, 55,842, 55
Colectomy 44,241, 44,160, 44,205, 44,145, 44,207, 44
44,155, 44,212, 44,140, 44,141, 44,143,
44,146, 44,147, 44,151, 44,208
Pancreatectomy 48,150, 48,152, 48,153, 48,154, 48,155, 48
48,146
Esophagectomy 43,107, 43,112, 43,117, 43,121, 43,122, 43
43,113, 43,116, 43,118, 43,123, 42,124
Hysterectomy 58,150, 58,152, 58,180, 58,200, 58,210, 58
58,262, 58,263, 58,267, 58,270, 58,275,
58,285, 58,290, 58,291, 58,292, 58,293,
58,541, 58,542, 58,543, 58,544, 58,548,
58,552, 58,553, 58,554
Hepatectomy 47,120, 47,122, 47,125, 47,130
Breast resection 19,120, 12,125, 19,260, 19,271, 19,272, 19
19,302, 19,303, 19,304, 19,305, 19,306,
Cystectomy 51,550, 51,555, 51,565, 51,570, 51,575, 51
51,590, 51,595, 51,596, 51,597
Nephrectomy 50,220, 50,225, 50,230, 50,234, 50,236, 50
50,545, 50,547, 50,548used to identify cancer operations
ICD-9 diagnosis code
,845, 55,866 185. XX, 187. XX, 233. XX
,150, 44,210,
44,144,
151-154.1, 157-159. XX, 195-202. XX, 209. XX,
230-239. XX
,140, 48,145, 151-152. XX, 155-159. XX, 194-199. XX, 209.
XX, 230-239. XX
,125, 43,108, 140-151. XX, 157-158. XX, 162-165. XX, 171.
XX, 195-208. XX, 230-239. XX
,240, 58,260,
58,280,
58,294,
58,550,
151. XX, 153-155. XX, 158. XX, 171. XX, 179-
208. XX, 230-239. XX
150-159. XX, 171. XX, 194. XX, 196-209. XX,
230. XX, 235. XX, 237. XX, 239. XX
,300, 19,301,
19,307
175. XX, 196-199. XX, 133-239. XX
,580, 51,585, 150-159. XX, 184-189. XX, 198. XX, 233. XX,
236. XX
,240, 50,543, 189, 195.2, 195.8, 198.0, 196. XX, 199. XX,
A
p
V
P
O
P
Bolded variables indicate P  .05.
JOURNAL OF VASCULAR SURGERY
Volume 55, Number 4 De Martino et al 1040.e2Appendix B (online only). Multivariate model for deep
venous thrombosis following selected cancer operations
Variable
Odds
ratio
95%
Confidence
interval P
Preoperative variables
Male 1.1 0.9-1.4 .18
Distant cancer 1.2 0.9-1.5 .15
Steroid 1.5 1.0-2.3 .04
Age
50 Ref
50-59 1.0 0.7-1.4 .84
60-69 1.6 1.2-2.2 <.01
70-79 1.6 1.2-2.2 <.01
80 1.8 1.2-2.5 <.01
Body mass index
25-30 Ref
25 1.0 0.8-1.2 .78
30-34 1.1 0.9-1.5 .27
>35 1.5 1.2-2.0 <.01
Albumin
3 Ref
3 1.2 0.9-1.6 .1
Platelets
100-400 K Ref
100 K 1.0 0.6-1.8 1.0
400 K 0.9 0.7-1.2 .5
Missing 1.0 0.6-1.6 1.0
Operative variables
Operating time (minutes) 1.0 1.0-1.001 <.01
Case
Breast resection Ref
Gastrectomy 1.6 0.8-3.0 .17
Lung resection 1.8 0.8-3.7 .12
Prostatectomy 2.5 1.2-5.0 .01
Colectomy 2.1 1.2-3.8 <.01
Pancreatectomy 1.6 0.1-2.9 .15
Esophagectomy 3.6 1.9-7.0 <.01
Hysterectomy 2.9 1.4-6.0 <.01
Hepatectomy 2.2 1.2-4.1 .01
Cystectomy 1.6 0.6-4.1 .29
Nephrectomy 1.3 0.5-3.5 .63
Transfusion
Zero Ref
1-2 units 1.2 0.9-1.5 .13
3-4 units 1.5 1.1-2.1 .02
5-9 units 1.7 1.1-2.7 .01
10-19 units 3.4 1.9-6.3 <.01
20 units 1.2 0.3-5.1 .78
Postoperative variables
Deep infection 1.5 1.2-1.9 <.01
Reintubated 1.5 1.2-2.0 <.01
Pulmonary embolism 11.5 8.9-15.0 <.01
Peripheral nerve injury 6.9 2.5-19.2 <.01
Sepsis postoperative 1.5 1.2-2.0 <.01
Shock postoperative 1.5 1.1-2.1 <.01
Total length of stay
1 week Ref
1-2 weeks 2.9 2.2-3.7 <.01
2-3 weeks 5.3 4.0-7.2 <.01
3-4 weeks 6.0 4.2-8.5 <.01
4-5 weeks 5.8 3.8-9.0 <.01
5-6 weeks 7.2 4.4-11.7 <.01
6-7 weeks 6.6 3.5-12.3 <.01
7-8 weeks 6.6 3.2-13.8 <.01
56-75 days 3.5 1.6-7.7 <.01
>75 days 4.9 1.9-12.1 <.01Bolded variables indicate P  .05.ppendix C (online only). Multivariate predictors of
ostoperative pulmonary embolus
ariable
Odds
ratio
95%
Confidence
interval P
reoperative variables
Male 1.0 0.8-1.3 .82
Distant cancer 1.1 0.8-1.5 .64
Recent radiation
therapy 1.9 1.2-3.2 <.01
Age
50 Ref
50-59 0.9 0.6-1.3 .49
60-69 1.2 0.8-1.7 .35
70-79 1.3 0.9-1.8 .21
80 1.0 0.6-1.5 .82
Body mass index
25-30 Ref
<25 0.7 0.5-0.9 <.01
30-34 1.1 0.8-1.4 .71
35 1.2 0.9-1.7 .21
Albumin
3 Ref
3 0.8 0.6-1.2 .23
Platelets
100-400 K Ref
100 K 0.8 0.3-1.8 .54
>400 K 1.5 1.1-2.0 .01
Missing 0.8 0.4-1.4 .43
perative variables
Case
Breast resection Ref
Gastrectomy 3.0 1.4-6.6 <.01
Lung resection 3.9 1.7-9.1 <.01
Prostatectomy 3.8 1.6-8.9 <.01
Colectomy 2.8 1.4-5.7 <.01
Pancreatectomy 2.9 1.4-6.0 <.01
Esophagectomy 2.2 0.9-5.2 .08
Hysterectomy 5.5 2.4-12.6 <.01
Hepatectomy 3.8 1.8-8.3 .01
Cystectomy 6.4 2.4-17.0 <.01
Nephrectomy 4.0 1.5-10.8 <.01
ostoperative variables
Deep infection 1.4 1.0-2.0 .03
Reintubated 2.0 1.4-2.8 <.01
Deep vein thrombosis 11.2 8.6-14.6 <.01
Postoperative dialysis 0.4 0.2-0.8 .02
Urinary tract infection 1.8 1.3-2.5 <.01
Cardiac arrest 3.1 1.9-5.2 <.01
Postoperative hospital
stay
1 week Ref
1-2 weeks 3.0 2.3-4.0 <.01
2-3 weeks 3.9 2.7-5.5 <.01
3-4 weeks 4.0 2.6-6.4 <.01
4-5 weeks 3.8 2.2-6.7 <.01
5-6 weeks 6.3 3.5-11.2 <.01
6-7 weeks 3.6 1.5-8.7 <.01
7-8 weeks 4.4 1.6-12.1 <.01
56-75 days 6.4 2.3-14.7 <.01
75 days 1.1 0.1-8.1 .96
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Preoperative variables
Male (%) Operative variables
Inpatient vs outpatient Emergent case
Age Wound
General anesthesia type American Society of Anesthesiologists class
Surgeon specialty Number of operative transfusions
Body mass index Total operative time
Diabetes
Pack years of smoking Postoperative variables
Dyspnea Superficial surgical site infection
Functional status prior to current illness Deep surgical site infection
Functional status prior to surgery Organ space surgical site infection
Severe chronic obstructive pulmonary disease Wound disruption
Current pneumonia Pneumonia
Ascites Unplanned intubation
Congestive heart failure Ventilator 48 hours
Myocardial infarction last 6 months Progressive renal insufficiency
Hypertension requiring meds Acute renal failure
Peripheral vascular disease Urinary tract infection
Impaired sensorium Cerebrovascular accident/stroke with deficit
Hemiplegia Coma 24 hours
Disseminated cancer Paraplegia
Open wound Cardiac arrest
Steroid use Myocardial infarction
10% weight loss Bleeding transfusions
Bleeding disorder Postoperative sepsis
Transfused 4 pints red blood cells before surgery Septic shock
Recent chemotherapy Days from operating room to discharge
Recent radiation Length of total hospital stay
Preoperative sepsis Admission to operation (days)
Preoperative sodium
Preoperative blood urea nitrogen
Preoperative albumin
Preoperative hematocrit
Preoperative partial thromboplastin time
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postoperative venous thromboembolic events
Variable
Odds
ratio
95% confidence
interval P
Preoperative variables
Male 1.1 0.2-1.2 .43
Distant cancer 1.2 1.0-1.5 .10
Outpatient status 0.5 0.2-0.9 .02
Recent steroids 1.4 1.01-2.0 .04
Days from admission to
surgery 0.9 0.9-0.97 <.01
Age
50 Ref
50-59 0.9 0.7-1.2 .37
60-69 1.4 1.1-1.8 <.01
70-79 1.4 1.1-1.9 <.01
80 1.3 1.0-1.7 .06
Body mass index
25-30 Ref
<25 0.8 0.7-0.9 .04
30-34 1.1 0.9-1.4 .25
>35 1.3 1.1-1.7 <.01
Albumin
3 Ref
3 1.2 1.0-1.5 .09
Platelets
100-400 K Ref
100 K 0.8 0.5-1.4 .42
400 K 1.1 0.9-1.4 .40
Missing 0.9 0.6-1.3 .46
Operative variables
Operating time (minutes) 1.0 0.9-1.0 .96
Case
Breast resection Ref
Gastrectomy 1.3 0.7-2.4 .37
Lung resection 1.8 0.9-3.3 .08
Prostatectomy 2.2 1.2-4.0 .01
Colectomy 1.7 1.0-2.9 .05
Pancreatectomy 1.3 0.8-2.3 .32
Esophagectomy 2.3 1.2-4.1 <.01
Hysterectomy 2.7 1.4-5.0 <.01
Hepatectomy 1.9 1.1-3.4 .0
Cystectomy 1.8 0.9-3.9 .1
Nephrectomy 1.7 0.8-3.5 .2
Transfusion
Zero Ref
1-2 units 1.3 1.1-1.6 <.01
3-4 units 1.3 1.0-1.8 .05
5-9 units 1.7 1.2-2.4 <.01
10-19 units 2.3 1.3-4.1 <.01
20 units 1.6 0.6-4.7 .39
Postoperative variables
Deep infection 1.5 1.2-1.9 <.01
Reintubated 1.7 1.4-2.2 <.01
Cardiac arrest 1.9 1.3-2.8 <.01
Sepsis postoperative 1.4 1.1-1.7 <.01
Shock postoperative 1.3 1.0-1.7 .04
Postoperative hospital
stay
1 week Ref
1-2 weeks 3.4 2.8-4.1 <.01
2-3 weeks 6.3 5.0-8.1 <.01
3-4 weeks 7.6 5.7-10.3 <.01
4-5 weeks 7.9 5.5-11.3 <.01
5-6 weeks 11.7 7.8-17.5 <.01
6-7 weeks 8.5 4.9-14.7 <.01
7-8 weeks 8.7 4.6-16.7 <.01
56-75 days 7.9 4.4-14.1 <.01
>75 days 4.2 1.7-10.2 <.01Bolded variables indicate P  .05.
